Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly & Co

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Fortune

Tech Stock Strength Lifts the Broader Market

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.16%. Strength in tech stocks today is lifting the broader market. Alphabet is up more...

Barchart

Stocks Turn Lower on Negative Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.03%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.50%. Stocks today gave up overnight gains and turned lower on some negative corporate news....

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA approves Zepbound, a new obesity drug that will take on Wegovy

Eli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.

WEKU

Eli Lilly, insulin makers sued by California over prices

Eli Lilly & Co., Novo Nordisk AS and Sanofi were sued by California over insulin prices, which the state claims are inflated through unfair and deceptive practices and disproportionately affect low-income households and people of color.

Tribune News Service

Tech’s tectonic plates are shifting — will Twitter, Meta and the other giants survive?

Amid job losses and tumbling share prices, all the platforms once thought too big to fail are now fighting to stay relevant. From Twitter to Meta, change is afoot, says John Arlidge

Evening Standard

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Advanced Micro Devices

Dow Jones Industrials

209 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.